Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.41 |
| ▸ | ACSL3 | O95573 | 1/20 | 0.41 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615769 | 0.90 | CHRNA7 (1.00) | CHRNA7KCNH2TTRNPC1RAB9A | |
| SCHEMBL1791588 | 0.90 | CHRNA7 (1.00) | CHRNA7KCNH2TTRNPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL1796865 | 0.88 | CHRNA7 (0.61) | CHRNA7KCNH2TTRNPC1RAB9A | |
| SCHEMBL1793910 | 0.78 | CHRNA7 (0.66) | CHRNA7KCNH2TTRNPC1RAB9A | |
| SCHEMBL1797602 | 0.78 | CHRNA7 (0.76) | CHRNA7KCNH2NPC1RAB9ATBK1 | |
| SCHEMBL1795700 | 0.76 | CHRNA7 (0.73) | CHRNA7KCNH2TTRNPC1RAB9A | |
| SCHEMBL1794533 | 0.76 | CHRNA7 (0.72) | CHRNA7KCNH2NPC1RAB9ATBK1 | |
| SCHEMBL1794936 | 0.76 | CHRNA7 (0.72) | CHRNA7KCNH2NPC1RAB9A | |
| SCHEMBL1797566 | 0.75 | CHRNA7 (0.71) | CHRNA7KCNH2TBK1 | |
| Hydrochloric Acid SCHEMBL1794591 | 0.74 | CHRNA7 (0.70) | CHRNA7KCNH2TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | CHRNA7 8/4885KCNH2 535/4885TTR 2572/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | CHRNA7 5/4885KCNH2 383/4885TTR 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.